MedXCell pipeline company CYTEA|BIO to attend the Jefferies Healthcare Conference in London (November 15-17, 2022)

Montreux, Switzerland | November 2, 2022 – CYTEA|BIO, a preclinical-stage biotechnology company focusing on allogeneic cellular immunotherapies combining non genetically modified effector cells (such as NK cells and macrophages) with targeting ligands, announced today that the company has been invited to attend the upcoming Jefferies Healthcare Conference. The conference will be held in London from November 15-17, 2022.
The Jefferies Healthcare Conference is the largest healthcare-dedicated investor conference in Europe covering pharma, biotech, medtech and healthcare services. The past conference saw 550 companies and 3,000 attendees from Americas, Europe, Middle East, Africa, and Asia join the event.
The conference features leading public companies and private companies at different stages of preparation for an IPO and/or companies that are looking for partnering and other business development opportunities.
CYTEA|BIO will be represented at the conference by Dr. Alan Cookson, CEO and Lionel Brodard, CFO.


CYTEA|BIO is a preclinical-stage biotechnology company focusing on allogeneic cellular immunotherapies. The company has developed and patented the Pin™ platform, a versatile and modular cell therapy platform enabling the combination of unmodified immune effector cells and targeting ligands. The company is the first pipeline company of MedXCell.


MedXCell is a European cell therapy venture builder with offices in Switzerland, France and the US. MedXCell focuses on technologies, techniques or novel applications in major diseases such as cancer, autoimmune, neurological and degenerative disorders, with the aim to turn promising academic ideas into commercially viable propositions.

For more information, please contact:

Lionel Brodard, CFO